The Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a CAR-T that treats diffuse large B cell lymphoma. Liso-cel was among the assets acquired when BMS bought Celgene for $74 billion in late 2019. (Endpoints News)

The declining number of COVID-19 cases in Israel suggests that a robust vaccination program can have a profound effect on infection rates. Early data from the Israeli program show that the vaccines are performing as well in the real world as they did during clinical trials. (The New York Times)

Walgreens, CVS and other retail pharmacies have bulked up their cybersecurity against the threat of bots designed to snap up available COVID-19 vaccination appointments. The Biden administration announced this week that it will begin directly distributing one million doses per week to around 6,500 pharmacies. (Reuters)

With the Johnson & Johnson coronavirus vaccine likely to receive emergency use authorization by month’s end, public health officials are worrying that not enough people will want it. The J&J vaccine was 72% effective in preventing moderate and severe disease in a U.S. clinical trial, while the Pfizer/BioNTech and Moderna vaccines were more than 94% effective. Scientists downplayed the significance of the differences. (Los Angeles Times)

The number of COVID-19 cases at U.S. elder-care residences has fallen. Health officials attribute the declines to better preventative measures and the gradual rollout of vaccines. (Associated Press)